rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Bausch Health Companies Inc.

BHC · NYSE

Health CarePharmaceuticalsJust started moving

BHC stood above a rising 150-day average in 12 of the last 52 weekly readings, including each of the last 1 week. It is 13.4% above that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
1 in a row
Industry in uptrend
32% -7 in 4 wk
Insider buys, 12 months
$15.6M
Insider sales, 12 months
$1.0M
Officials’ trades on record
3
Institutions holding
211 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.

20 Apr – 19 Oct
26%34%43%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$321.7MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

3 disclosed lines: House 3, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Susie Lee House: U.S. House ClerkNV03sold$1k–$15k27 Aug 2020filed 7 Oct 2020
Susie Lee House: U.S. House ClerkNV03boughtjoint$1k–$15k24 Feb 2020filed 28 Apr 2020
Susie Lee House: U.S. House ClerkNV03bought$1k–$15k6 Jan 2020filed 25 Feb 2020

Insiders

Buy orders, 12 months1
Sale orders, 12 months5
Buyers · sellers1 · 3
WhoDidSharesTraded
Aimee J. LenarPresident, US Pharmasold36,827at $7.0319 Aug 2026filed 20 Aug 2026
Frank D. LeeDirectorsold24,456at $5.4319 May 2026filed 20 May 2026
Seana CarsonEVP, General Counselsold4,420at $5.773 Mar 2026filed 3 Mar 2026
Seana CarsonEVP, General Counselsold6,856at $5.782 Mar 2026filed 3 Mar 2026
Seana CarsonEVP, General Counselsold8,388at $5.9527 Feb 2026filed 27 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders211-2 on the quarter
New · exited30 · 33
Reported value$1.1B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
PAULSON & CO. INC.unchanged · filed 14 Aug 202673,255,869$361.2M00.0%
GOLDENTREE ASSET MANAGEMENT LPunchanged · filed 14 Aug 202634,665,731$170.7M00.0%
ROYAL BANK OF CANADAreduced · filed 14 Aug 202610,832,582$53.4M-530,916−4.7%
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDunchanged · filed 13 Aug 20268,000,000$39.4M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,465,468$36.8M+61,709+0.8%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20266,225,131$30.7M+1,017,165+19.5%
MFN Partners Management, LPunchanged · filed 12 Aug 20266,000,000$29.6M00.0%
Kohlberg Kravis Roberts & Co. L.P.unchanged · filed 14 Aug 20265,235,000$25.8M00.0%
ING GROEP NVunchanged · filed 13 Aug 20265,000,000$24.6M00.0%
Hudson Bay Capital Management LPunchanged · filed 14 Aug 20265,000,000$24.6M00.0%
31 Mar 2023 – 30 Jun 2026
192206220Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Amy B. Wechsler Company insiderDirector · last 30 Sep 20260 · 1
John Paulson Company insiderDirector · last 30 Sep 202613 · 2
Sandra Leung Company insiderDirector · last 30 Sep 20260 · 0
Aimee J. Lenar Company insiderPresident, US Pharma · last 19 Aug 20260 · 1
Steven Hyosig Lee Company insiderSVP, Controller & CAO · last 14 Jul 20260 · 0
Christian A. Garcia Company insiderDirector · last 22 May 20260 · 0
Eiry Roberts Company insiderDirector · last 22 May 20260 · 0
Frank D. Lee Company insiderDirector · last 22 May 20260 · 2
Michael Goettler Company insiderDirector · last 22 May 20260 · 0
Robert N. Power Company insiderDirector · last 22 May 20260 · 0
Sarah B. Kavanagh Company insiderDirector · last 22 May 20260 · 0
Seana Carson Company insiderEVP, General Counsel · last 3 Mar 20260 · 13

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 202517.7%
Free cash flow marginFY 2025 · to 31 Dec 20259.8%
Return on capital employedFY 2025 · to 31 Dec 20258.2%
Cash conversionFY 2025 · to 31 Dec 2025892%
Interest coverFY 2025 · to 31 Dec 20251.13×
Share count trendFY 2025 · to 13 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.3B
Free cash flowFY 2025 · to 31 Dec 2025$1.0B

Analyst forecasts

No analyst forecasts yet.